1. **Treatment & Condition**
   Tofacitinib for moderately to severely active ulcerative colitis

2. **Associated appraisal body & Summary of ruling**
   NICE Technology Appraisal guidance TA547 (November 2018)
   Tofacitinib (Xeljanz®) is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment. It is recommended only if the company provides tofacitinib with the discount agreed in the commercial arrangement.

3. **Number of people in Northern Ireland expected to take up service/therapy**
   According to the Resource Impact Template that accompanies NICE TA547, it is expected that by year five 79 people in Northern Ireland will take up treatment with tofacitinib in line with this guidance.

4. **Patient Access Scheme Availability**
   *(Yes/No)*
   The company (Pfizer) has a commercial arrangement. This makes tofacitinib available to the NHS with a discount. The size of the discount is commercial-in-confidence.

5. **Infrastructure Requirements**
   Any additional infrastructure costs associated with the introduction of this medicine for this indication will be dealt with as part of the routine commissioning process.

6. **Expected implementation period**
   There is no impediment to implementation of this guidance.

7. **Commissioning arrangements**
   This regime will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost per case basis.

8. **Monitoring arrangements**
   The HSC Board has robust arrangements in place for the monitoring of all biologic therapies (patient numbers and waiting times), and this regime will be included within the routinely provided return.
All monitoring returns for biologics are reviewed by the specialist services commissioning team.

<table>
<thead>
<tr>
<th>9.</th>
<th><strong>DoH (NI) Legislative/Policy Caveats</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</td>
</tr>
<tr>
<td></td>
<td>The Rural Needs Act (NI) 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the Act.</td>
</tr>
</tbody>
</table>